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Psychiatry 
The Use of Propranolol in the Treatment of Post-traumatic Stress Disorder 
Tana M Petemian, fou1h·year pharmacy major from Jacksonvdle, N.C . Ahsan L Huet, fourth·year pharmacy rnaior from P1ttslxirgh, Pa. 
Sarah E. Drake, fourth-year pharmacy rnapr from Fairlield, Ohio, Jamie L Drees, hfth·year phannacy maior from Canal Wincl-ester, Ohio, 
Robert D. Raiff, ftfth·year phamiacy mapr from Westlake, Ohio. B. Shane Martin, PharmD 
Abstract 
This article exammes the nsmg tsSue of p?St-traumatic stress disorder 
(PTSD) and possible treatment options. PTSD is a behavioral disorder 
resulting from memory formation and association with a traumatic evenL 
A search of the p.iblished literature reveals several positive studies and 
case reports suggesting that propranolol, a beta adrenergic receptor 
antagonist, may be useful for ooth treatment and prevention of PTSD. 
Additionally, current studies are being completed m differem populallon 
gro!J~ to detenrnne the overall effectiveness and mechanism by which 
propranolol is able to provide relief from certain symptoms common to 
the disorder. ThJS article d1SCusses the medical evidence and p?ssible 
treatment role of propranolol for ~t1ems sufienng from PTSD. 
Background 
Post-traumatJc stress disorder (PTSD) is defined by DSM-IV as a traumallC 
incident in which a person experiences a lrfe-threatening event that involves 
extreme fear that IS pers1Stently re-expenenced.1 PTSD is partlcularly 
seen m military veterans, including 29 percent of combat veterans and 78 
percent of pnsoners of war. Besides military-related causes, automobile ac-
cidents account for 56 percent of cases, and personal assault accounts for 
35 percent of PTSO cases.2 In order to be diagnosed with PTSD, a patient 
must be expeliencing symptomology greater than one month after the 
traumatic incident 1 Clinical characteristics of PTSD include re-experiencing 
symptoms, avoidance of certain situations, and hyperarousal symptoms 
along with the possibility otother mJScellaneous symptoms (Table 1). 
These characteristics can cause social, occupational and relational 
dysfunction. PTSD can be classified based on the occurrence and duraoon 
of these charactenstics. If the patient experiences symptoms for less than 
three months after the incident, 1t 1s considered acute PTSD. The expen-
encing of symptoms greater than three months class ifies patients as haVlng 
chronic PTSO. Finally, a paoont who does not experience these 1nd1cators 
until six months alter the event are considered to have delay-onset PTSD.1 
Table 1: Classic PTSD Characteristics 
Classification Examples 
Re-ex~riencing Symporns Flashbacks, nightmares, frightening thoughts 
Avoidaoce Symporns Staying away from i:Aaces, events and oqects 
that are reminders of traumatic event 
Hy~rarousal Symporns Easily startled, feeling tense, difficulty 
sleeping, angry outbursts 
Other Syrnpoms Feeling erootional numbness, guilt, worry, 
depression, rnem:iry loss 
There are a variety of options for PTSD treatment ranging from pharmaco-
logical 1ntervenoons to ~ycholherapy. The first-Ima pharmacologic trear-
ment is the use of selecnve serotonin reuptake inhibitors (SSRls) to reduce 
clinical symptoms, including suicidal and aggressive behaviors. Some com-
monly used FDA-approved SSRls are paroxetine and sertrahne. Psycho-
therapy can be used man effort lo desensitize PTSD patients to triggers, 
which can be anything that reminds patients of the traumatic event, includ-
ing plac:Gs, sounds and smells.1•4.S For example, a trigger ror a war veteran 
may be the sound of a heltcopter or an unexpected loud noise.6 
Rationale and evidence 
A current area of research for the treatment of PTSD is the use of 
propranolol, a nonselect1ve beta-adrenergic antagonist that crosses the 
blood brain barrier. Its current indications include hypertension, angina, 
supraventricular arrhythmias, tachycardia, migrame headache prophy-
laxis and myocardial infarction prevention.4 Propranolol generally has 
mild and temporary side effects, including sinus bradycardia, hypoten-
sion, lethargy, dimness, nausea and vomiting. Patients with PTSD cyp1-
cally have higher levels of norepinephnne and epinephrine, which induce 
stress. Epinephrine is thought to aid in memory consolidation, playing 
a role m the re-experiencing symptoms of PTSD.7 Beta-blockers inhibit 
the binding of these neurotransmitcers at the receptors (beta-1 and 
beta-2 for epinephrine, beta· 1 for norepmephnne), the proposed clinical 
mechanism of propranoloi.& The beta-adrenerg1c system 1s associated 
with response and memory forma tion as well as the emotional response 
associaled with the memory. Propranolol may both dampen memory 
formation and dissociate the memory from the emotional response. 
Although this treatment has been termed "forgetllng therapy," it 1s not 
meant to make individuals forget their physical experiences but rather 
enable them to dissociate the emotions and tears from the memories.9 
In a randomized, double-blind study, 19 subpcts were treated with 
either propranolol or placebo to determine its effects on PTS0.10The 
patients had been diagnosed with PTSD according to the DSM-IV 
criteria. Traumatic events experienced by individuals in this study in-
cluded childhood sexual abuse, car accidents, rape, hostage situations , 
witnessing or experiencing physical assaults, death threats , and house 
fires. The study began with the preparation of two 20-minute written 
scnpts that investigators turned into 30-second recordings for each pa-
tient, including elements of the traumatic expenences that caused their 
PTSD. Patients !hen received either 40 mg ofshon-actJng propranolol 
(nine panents) or an ldenucal placebo (10 pa.nenrs). lfthe first dose was 
well-tolerated, the study group received 60 mg of long-acnng propranolol 
two hours later, while the control group received the placebo. One week 
later, patents underwent a script-driven imagery procedure where the 
patients listened to the 30-second recorded scripts and were then asked 
to tmagtne the event for 30 seconds. Heart rate (HR), skm conductance 
(SC) and left corrugator electromyogram (EMG) were recorded. The 
responses were calculated by subtracting baseline measurements 
from the average measurements taken during the imagery procedure. 
Add1tionally, data from a similar previous study of 152 patients with and 
without PTSO were included to determine optinal cutoffs for HR, SC and 
EMG in PTSD patients. The results of the study show that physiological 
responses to mental imagery of the events were significantly smaller in 
the propranolol group compared to the placebo. The univariate analysis 
showed that HR and SC, but not EMG, responses were significantly 
smaller in the propranolol group. The HR and SC responses for the 
propranolol group were below the normal cutoffs for PTSD. The placebo 
group's responses were still above the normal cutoff. The EMG for both 
grou~ fell below the normal cutoff. The study suggests that propranolol 
1s effective m controlling physiologic responses to traumabc events m 
patients 1f administered after recurrent memones. ThtS evidence lends 
support towards the rationale of treating certain PTSD patients with 
propranolol. 
A casG mport, publishGd in 2002, dGscnbGs thG 9ff9cts of propranolol 
on a case of re-emergent PTSD after retraumatizatton. A 44-year-old 
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Caucasian female experienced fiva motor vehicle accidents within a 
10-year time frame. Of the five motor vehicle accidents, the last three 
caused the pa.Dent to develop PTSD lasting over six months. It was not 
untll after the third motor vehicle accident that she immediately began 
expenencing severe PTSD symptoms, including recurrent memones 
of the event, nightmares, insomnia, flashbacks, irritability and avo1dant 
behavior. Over the span of the seven years that the patient suffered from 
PTSD, treatment methods included counseling, cognitive and behav-
ioral therapy, and drug regimen trials, including sertraline , im1pramme, 
tamazepam and paroxetine with the addition of clonazepam as needed. 
The patient's PTSD symptoms persisted over the next three years, 
which gradually dissipated and resolved. Forty-eight hours after her SIXth 
motor vehicle accident, the patient was prescribed propranolol 60 mg 
to be taken orally twice a day. The Clinician-Adminis tered PTSD Scale 
(CAPS-Sx) was used to measure changes in PTSD symptoms before, 
during and alter the propranolol treatment. Her first CAPS-Sx score was 
86 prior to adm1n1Srraoon of the propranolol, at the day-1 1 follow-up 
visit. the score had dropped to 56. The patient reported feeling much 
improved as quickly as 48 hours after receiving the propranolol and con-
tinued to report improvement until her prescription ran out rwo months 
later. The patient's PTSD symptoms resurfaced; therefore, her treatment 
was resumed. At nine months post-trauma, her CAPS-Sx score was 
down to 25. her propranolol was discontinued. and she experienced no 
withdrawal side effects or re-emergence of symptoms.11 
Future evidence 
A 14-week, randomized, double-blind study is currently being conducted 
to compare propranolol to placebc treatment in PTSD patients. Patients 
wi ll attend an initial visit, where a medical and psychiatric history review 
wi ll be obtained, along with a psychiatric interview and symptom ques-
tionnaires. Patients with either a DSM-IV diagnosis of PTSD or those 
meeting five of the six diagnostic criteria for PTSD will be randomly as-
signed to take a test dose of propranolol or placebo. Following this, pa-
tients will be instructed to take Hie medication subsequent to a traumatic 
memory associated with hyperarousal symptoms. The patient will utilize 
a maximum of two doses per day mat must be separated by at least six 
hours. Patients will also use a cognitive therapy-based workbook to track 
symptoms daily as well as any attempts to use cognitive techniques to 
relieve symptoms. In addillOn, pabents will attend visits with invesogators 
every two weeks to revtew workbcokS with study officials, pick up medi· 
cation, d1Scuss side effects, and complete interviews and questionnaires 
about symptoms. At the conclus10n of the trial, a CAPS·Sx Seventy 
Scale will be administered ro assess PTSD symptom control, and this 
wi ll be used as the pnmary outcome measure. Secondary outcomes 
will be measured by the Beck Depression lnvento1y, a Post-Traumatic 
Scale-Self Score and a Brief Symptoms Inventory-Short Form.1i 
Another randomized, double-blind study being pursued is the use 
of propranolol in reducing PTSD symptoms through memory recon-
solidation in veterans of the wars in Afghanistan and Iraq. As previ-
ously stated, it is thought that epinephrine plays a role in strengthen-
ing memory consorldation, which lgads to persistent memory of the 
traumatic evem(s) for PTSD patients. The idea behind this study using 
propranolot IS to weaken memory reconsolidat1on by using the drug to 
block epinephnne bmding. Patients 1n this study will be randomized into 
either a non-reactivation propranolol group or a post-reactivation pro-
pranolol group. Al Che first v1s1t, non-reactivation propranolol patients will 
be given propranolol, and post-reactJvarion propra nolol patients will be 
given a placebo. Two days later, both groups will recall their traumalie 
event for scnpt preparanon, wliich will trigger the memory reactivation. 
The non-reactivation propranolol group will receive a placebo, while the 
post-reactlvaoon propranolol group will receive propranolol. The pnmary 
outcome measure at week one and six months will be psychophysiotogic 
responses to scnpt-drlven imagery. The antic1paoon 1s that the post-react1-
vaoon propranotol group will exhibit fewer and less severe responses.7 
Based on small clinical studies conducted, propranolol may be a viable 
treatment option for certain PTSD patients. Compared to pl.acebo, small 
chmcal studies have shown propranolol may have significant impact on 
PTSD symptoms. especially re-experiencing and hyperarousal symptoms. 
Studies comparing it to other treatment options (SSRls. tricyclic antide-
pressants and MAO inhibitors) are limited, and more research needs to be 
conducted. Propranolol is not currently a first-line therapy, but for those 
patients that are unresponsive to othertreatment options. it should be 
considered as a means to manage PTSD symptoms. 
This is an area of increasing importance to study due to the prevalence 
of war veterans returning home. PTSD is thought to occur in 11-20 percent 
of veterans of the wars in Afghanistan and Iraq. PTSD has an impact on 
quality of life for veterans and their families. Veterans who suffer from 
thlS disease may be more prone to develop substance abuse problems, 
personality disturbances and cnminal behavior compared ro the general 
population. Another problem that the veterans face IS su1cldal tendenc1es.13 
As troops con tinue to be deployed, it is important to explore new treatment 
opoons since the numbers of PTSD patients is likely to increase. Besides 
treatment, studies are being conducted to research propranolol in the 
prevenaon of PTSD, which may be beneficial ;o m11ttary personnel as well 
as the c1v11ian population. However, the prophylactic use of propranotol in 
the mffitary IS controvers1al.9 
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